Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
Adam Ioannou, Marianna Fontana, Julian D. Gillmore
BioDrugs (2023) Vol. 37, Iss. 2, pp. 127-142
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis
Adam Ioannou, Francesco Cappelli, Michele Emdin, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 14, pp. 1276-1291
Open Access | Times Cited: 28
Eplontersen: First Approval
Tina Nie
Drugs (2024) Vol. 84, Iss. 4, pp. 473-478
Open Access | Times Cited: 17
The Last Decade in Cardiac Amyloidosis
Alberico Del Torto, Adam Ioannou, Sarah Cuddy, et al.
JACC. Cardiovascular imaging (2025)
Open Access | Times Cited: 2
Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine
Esther Gonzalez-Lopez, Mathew S. Maurer, Pablo García‐Pavía
European Heart Journal (2025)
Open Access | Times Cited: 2
Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis
Adam Ioannou, Carlo Fumagalli, Yousuf Razvi, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 1, pp. 43-58
Open Access | Times Cited: 15
Gene therapy clinical trials worldwide to 2023—an update
Samantha L. Ginn, Mawj Mandwie, Ian E. Alexander, et al.
The Journal of Gene Medicine (2024) Vol. 26, Iss. 8
Closed Access | Times Cited: 12
Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy
David Adams, Jonas Wixner, Michael Polydefkis, et al.
JAMA Neurology (2025)
Closed Access | Times Cited: 1
Gene therapy for ultrarare diseases: a geneticist’s perspective
Wuh‐Liang Hwu
Journal of Biomedical Science (2024) Vol. 31, Iss. 1
Open Access | Times Cited: 7
Current Therapies and Future Horizons in Cardiac Amyloidosis Treatment
J Vogel, Alexander Carpinteiro, Peter Luedike, et al.
Current Heart Failure Reports (2024) Vol. 21, Iss. 4, pp. 305-321
Open Access | Times Cited: 6
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Tina Nie, Young‐A Heo, Matt Shirley
Drugs (2023) Vol. 83, Iss. 15, pp. 1425-1432
Closed Access | Times Cited: 15
Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy
Violaine Planté‐Bordeneuve, Valentine Perrain
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 4, pp. 393-402
Open Access | Times Cited: 5
Hepatoprotective potential of Chrysin in a rat model of isoniazid- and rifampicin-induced hepatic injury: suppression of matrix metalloproteinase and transforming growth factor β
Deepa S. Mandlik, Akhilesh Tokey, Rahul Lokhande, et al.
Future Journal of Pharmaceutical Sciences (2025) Vol. 11, Iss. 1
Open Access
Translation of genomics into routine cardiological practice: insights from a European Society of Cardiology Cardiovascular Round Table
Stefanie Dimmeler, Leticia Ferri, Paul Nioi, et al.
European Heart Journal (2025)
Closed Access
Small interfering RNA: From designing to therapeutic in cancer
Jyoti Singh, Abdulaziz S. Saeedan, Gaurav Kaithwas, et al.
Journal of Genetic Engineering and Biotechnology (2025) Vol. 23, Iss. 2, pp. 100484-100484
Closed Access
Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
Adam Ioannou, Marianna Fontana, Julian D. Gillmore
Heart International (2023) Vol. 17, Iss. 1, pp. 27-27
Open Access | Times Cited: 12
Rare Forms of Cardiac Amyloidosis: Diagnostic Clues and Phenotype in Apo AI and AIV Amyloidosis
Adam Ioannou, Aldostefano Porcari, Rishi Patel, et al.
Circulation Cardiovascular Imaging (2023) Vol. 16, Iss. 7, pp. 523-535
Open Access | Times Cited: 12
RNA-based therapeutics for the treatment of blood disorders: A review and an overview
Prakas Kumar Mandal, Kaustav Ghosh
Journal of Hematology and Allied Sciences (2025) Vol. 5, pp. 47-53
Closed Access
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions
Yu Fu Ferrari Chen, Alberto Aimo, Vincenzo Castiglione, et al.
Current Heart Failure Reports (2025) Vol. 22, Iss. 1
Open Access
Rna-Targeting Therapies For Amyloid Transthyretin Cardiomyopathy: A Systematic Review And Meta-Analysis
João Victor de Oliveira Ramos, João Vítor Andrade Fernandes, Yan Gadelha de Abrantes Formiga, et al.
Current Problems in Cardiology (2025), pp. 103057-103057
Closed Access
OCT angiography indices and the choroidal vascularity index in wild-type transthyretin (TTR) amyloidosis (ATTRwt)
Michele Rinaldi, Fausto Tranfa, Flavia Chiosi, et al.
Frontiers in Medicine (2024) Vol. 10
Open Access | Times Cited: 3
Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis
Christian Nitsche, Adam Ioannou, Rishi Patel, et al.
European Journal of Heart Failure (2024)
Open Access | Times Cited: 3
Non-coding RNA therapeutics in cardiovascular diseases and risk factors: Systematic review
Meity Ardiana, Asiyah Nurul Fadila, Zakirah Zuhra, et al.
Non-coding RNA Research (2023) Vol. 8, Iss. 4, pp. 487-506
Open Access | Times Cited: 8
Enabling safer, more potent oligonucleotide therapeutics with bottlebrush polymer conjugates
Peiru Chen, Yun Wei, Tingyu Sun, et al.
Journal of Controlled Release (2023) Vol. 366, pp. 44-51
Closed Access | Times Cited: 7
Treatment of transthyretin cardiac amyloidosis
Dimitrios Bampatsias, Abdirahman Wardhere, Mathew S. Maurer
Current Opinion in Cardiology (2024) Vol. 39, Iss. 5, pp. 407-416
Closed Access | Times Cited: 2
Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis
Adam Ioannou
Heart International (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top